AstraZeneca PLC (AZN)vsXeris Pharmaceuticals Inc (XERS)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
XERS
Xeris Pharmaceuticals Inc
$6.53
-1.51%
HEALTHCARE · Cap: $1.14B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 20609% more annual revenue ($60.44B vs $291.85M). AZN leads profitability with a 17.2% profit margin vs 0.2%. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
XERS
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
+4.7%
Fair Value
$7.25
Current Price
$6.53
$0.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Revenue surging 42.8% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.2% margin — thin
Trading at 81.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : XERS
The strongest argument for XERS centers on Revenue Growth. Revenue growth of 42.8% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : XERS
The primary concerns for XERS are EPS Growth, Market Cap, Profit Margin. Thin 0.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while XERS is a hypergrowth play — different risk/reward profiles.
XERS carries more volatility with a beta of 0.92 — expect wider price swings.
XERS is growing revenue faster at 42.8% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 40/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Xeris Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?